AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7817169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin
Number of subjects: 48
Study 7817169 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin prophylaxis)
Number of subjects: 48
Study 3043128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoprotective antacidum (226 mval acid‐neutralisation‐capacity per day's dose)
Number of subjects: 60
Study 3043128 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (2x 400 mg)
Number of subjects: 60
Study 3043128 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination treatment of antacidum with Cimetidine for 1 week, followed by antacidum
Number of subjects: 60
Study 30788892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training
Number of subjects: 24
Study 30788892 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 24
Study 28336937 — intervention group
Group type: COMPARATOR
Intervention: FCR (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 200
Study 28336937 — intervention group
Group type: EXPERIMENTAL
Intervention: FCM-miniR (mitoxantrone with low-dose rituximab)
Number of subjects: 200
Study 25415549 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS + RTP
Number of subjects: 21
Study 25415549 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS + RTP
Number of subjects: 21
Study 23433258 — intervention group
Group type: EXPERIMENTAL
Intervention: UC simulation-based skills training
Number of subjects: 64
Study 23433258 — intervention group
Group type: COMPARATOR
Intervention: Video instruction before performance testing
Number of subjects: 64
Study 21666275 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study 21666275 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led supportive care
Number of subjects: 20
Study 19329405 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose multivitamin and mineral supplement (MMS)
Number of subjects: 128
Study 19329405 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 162 mg
Number of subjects: 128
Study 19329405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MMS
Number of subjects: 128
Study 19329405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 16394956 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO) - 1000 mg vitamin C and 300 mg RRR‐alpha‐tocopheryl acetate
Number of subjects: 22
Study 16394956 — intervention group
Group type: COMPARATOR
Intervention: Placebos (PL)
Number of subjects: 22
Study 16394956 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AO and PL)
Number of subjects: 22
Study 15280133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 240
Study 15280133 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 240
Study 11345029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain 50 mg (5 mg every second day for a total of 10 injections)
Number of subjects: 75
Study 11345029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain 100 mg (10 mg injections)
Number of subjects: 75
Study 11345029 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic corrective therapy (control group)
Number of subjects: 75
Study 8842603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 1 mg
Number of subjects: 304
Study 8842603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Number of subjects: 304
Study 8842603 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg
Number of subjects: 304
Study 8842603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 1622919 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg twice a day for 7 1/2 days starting the evening before the abortion
Number of subjects: 432
Study 1622919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 1622919 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin in women positive for C. trachomatis
Number of subjects: 432
Study 1622919 — intervention group
Group type: COMPARATOR
Intervention: Placebo in women positive for C. trachomatis
Number of subjects: 432
Study 6691563 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (4‐5 micrograms/kg intramuscularly 45‐90 min before induction)
Number of subjects: 100
Study 6691563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction)
Number of subjects: 100
Study 6691563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg orally with a sip of water 1‐4 hr before induction) + Glycopyrrolate (4‐5 micrograms/kg intramuscularly 45‐90 min before induction)
Number of subjects: 100
Study 6691563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 30021588 — intervention group
Group type: EXPERIMENTAL
Intervention: Best current treatment plus ultrasound-guided intra-articular hip injection of corticosteroid (triamcinolone acetonide 40 mg) with 1% lidocaine hydrochloride
Number of subjects: 204
Study 30021588 — intervention group
Group type: EXPERIMENTAL
Intervention: Best current treatment plus ultrasound-guided intra-articular hip injection of 1% lidocaine hydrochloride alone
Number of subjects: 204
Study 30021588 — intervention group
Group type: COMPARATOR
Intervention: Best current treatment alone
Number of subjects: 204
Study 28807059 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) dietary intervention, consisting of a two-hour dietary education session in early pregnancy.
Number of subjects: 625
Study 28807059 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 625
Study 25908114 — intervention group
Group type: EXPERIMENTAL
Intervention: Midregional proadrenomedullin (MR‐proADM)
Number of subjects: 2071
Study 25908114 — intervention group
Group type: COMPARATOR
Intervention: Troponin (cTnI)
Number of subjects: 2071
Study 24132714 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaired tetralogy of Fallot in women
Number of subjects: 272
Study 19915912 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (PEEP = 5 cmH(2)O)
Number of subjects: 30
Study 19915912 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (PEEP = 0 cmH(2)O)
Number of subjects: 30
Study 18338275 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐in‐1 block with 40 ml of 0.25% bupivacaine 30‐minutes before surgery
Number of subjects: 30
Study 18338275 — intervention group
Group type: COMPARATOR
Intervention: Simple needle puncture at the operation site 30‐minutes before surgery
Number of subjects: 30
Study 16901610 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed chest compressions
Number of subjects: 62
Study 16901610 — intervention group
Group type: COMPARATOR
Intervention: Two-handed chest compressions
Number of subjects: 62
Study 16901610 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for technique
Number of subjects: 62
Study 12801491 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous PC6 acupressure
Number of subjects: 301
Study 12801491 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 301
Study 12801491 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 301
Study 10983550 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 483
Study 7574952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin according to the 'Hammersmith' regimen
Number of subjects: 20
Study 7574952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2117207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (INO) supplementation (70‐100 mg/kg/day)
Number of subjects: 230
Study 2117207 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (INO) supplementation
Number of subjects: 230
Study 2117207 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose supplementation)
Number of subjects: 230
Study 7281089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 1
Number of subjects: 12
Study 7281089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 2
Number of subjects: 12
Study 7281089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 3
Number of subjects: 12
Study 7281089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated anti-smoking filter 4
Number of subjects: 12
Study 7281089 — intervention group
Group type: COMPARATOR
Intervention: Reference cigarette without anti-smoking filter
Number of subjects: 12
Study 30739376 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Number of subjects: 89
Study 30739376 — intervention group
Group type: COMPARATOR
Intervention: ClinOleic
Number of subjects: 89
Study 28682887 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5% eyedrops (ATE)
Number of subjects: 126
Study 28682887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25511794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 25511794 — intervention group
Group type: COMPARATOR
Intervention: Control (oseltamivir alone)
Number of subjects: 0
Study 24475598 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended teaching intervention (Internet-based tutorials + traditional lectures)
Number of subjects: 112
Study 24475598 — intervention group
Group type: COMPARATOR
Intervention: Conventional face-to-face classroom teaching
Number of subjects: 112
Study 21495829 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol/hydrochlorothiazide 5/6.25 mg
Number of subjects: 180
Study 21495829 — intervention group
Group type: COMPARATOR
Intervention: amlodipine/valsartan 5/160 mg
Number of subjects: 180
Study 20070722 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Number of subjects: 115
Study 20070722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endometrial biopsy)
Number of subjects: 115
Study 17295576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 127
Study 15323587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (300 mg/day, titrated upward)
Number of subjects: 40
Study 15323587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11257268 — intervention group
Group type: COMPARATOR
Intervention: GG genotype
Number of subjects: 387
Study 11257268 — intervention group
Group type: COMPARATOR
Intervention: DD genotype
Number of subjects: 387
Study 11257268 — intervention group
Group type: COMPARATOR
Intervention: DG genotype
Number of subjects: 387
Study 9875113 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary GTN (0.2 mg)
Number of subjects: 96
Study 9875113 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN spray (0.8 mg)
Number of subjects: 96
Study 9875113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual GTN capsule (0.8 mg)
Number of subjects: 96
Study 9054791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (graded activity and cognitive restructuring)
Number of subjects: 60
Study 9054791 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 60
Study 1686106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 1686106 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group (CS+ and CS- stimuli with electrical shock)
Number of subjects: 0
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group (CS+ and CS- stimuli during extinction)
Number of subjects: 0
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobic group (feared and non-feared cues)
Number of subjects: 0
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group (heart rate responses during acquisition)
Number of subjects: 0
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group (heart rate responses grouped into 2 trial blocks)
Number of subjects: 0
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning group (heart rate responses during extinction)
Number of subjects: 0
Study 7267929 — intervention group
Group type: EXPERIMENTAL
Intervention: Phobic group (heart rate responses to feared and unfeared cues)
Number of subjects: 0
Study 7267929 — intervention group
Group type: COMPARATOR
Intervention: Both groups (responses to neutral cues)
Number of subjects: 0
Study 31533823 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (60 min sessions for 8 weeks)
Number of subjects: 128
Study 31533823 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reminder e-mails
Number of subjects: 128
Study 31533823 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (receiving yoga 9 weeks later)
Number of subjects: 128
Study 29065076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load circuit resistance training protocol
Number of subjects: 42
Study 29065076 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training
Number of subjects: 42
Study 24526184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.5 mg)
Number of subjects: 16
Study 24526184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23986963 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine (CHX) rinse
Number of subjects: 12
Study 23986963 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil rinse containing ethanol
Number of subjects: 12
Study 23986963 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil rinse without ethanol
Number of subjects: 12
Study 23986963 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 12
Study 21055739 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 (10 mg)
Number of subjects: 26
Study 21055739 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 (20 mg)
Number of subjects: 26
Study 21055739 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 (10 mg) and CDB-2914 (20 mg)
Number of subjects: 26
Study 21055739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 26
Study 18204878 — intervention group
Group type: EXPERIMENTAL
Intervention: Durasphere anal injection (mean of 8.8 ml injected)
Number of subjects: 33
Study 17154744 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high-dose (35 mg) 24-hr patches
Number of subjects: 324
Study 17154744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 14585863 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 217
Study 14585863 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin plus amoxicillin
Number of subjects: 217
Study 11105974 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body restrictions (6 single restrictions at two severity levels and 2 multiple restrictions)
Number of subjects: 0
Study 11105974 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted control
Number of subjects: 0
Study 9055918 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy, 1 IU/kg/week, administered subcutaneously once daily
Number of subjects: 203
Study 9055918 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 203
Study 9055918 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 203
Study 1841830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (ivIgG) for prophylaxis of infection
Number of subjects: 0
Study 1841830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (ivIgG)
Number of subjects: 0
Study 6357269 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol therapy (mean dose of about 11.5 g starting at the 12th week of pregnancy)
Number of subjects: 650
Study 6357269 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo tablets)
Number of subjects: 650
Study 6357269 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol therapy
Number of subjects: 650
Study 31818692 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + CoQ10
Number of subjects: 0
Study 31818692 — intervention group
Group type: COMPARATOR
Intervention: Statin + Placebo
Number of subjects: 0
Study 30590472 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention focused on NMUPD
Number of subjects: 391
Study 30590472 — intervention group
Group type: COMPARATOR
Intervention: General health website
Number of subjects: 391
Study 28623122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 28623122 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-Pemetrexed
Number of subjects: 0
Study 27927226 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clearance required for higher-risk individuals
Number of subjects: 1244
Study 27927226 — intervention group
Group type: COMPARATOR
Intervention: Lower-risk individuals
Number of subjects: 1244
Study 25068207 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cellulose dried matrix spotting (DMS) cards
Number of subjects: 49
Study 25068207 — intervention group
Group type: COMPARATOR
Intervention: Filter paper (FP)
Number of subjects: 49
Study 22843087 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with bevacizumab
Number of subjects: 850
Study 22843087 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin without bevacizumab
Number of subjects: 850
Study 19288755 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiantongding Decoction
Number of subjects: 70
Study 19288755 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (Control)
Number of subjects: 70
Study 17311979 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (various strains including Lactobacillus rhamnosus GG, L. reuteri, L. casei, L. acidophilus, Escherichia coli strain Nissle 1917, certain bifidobacteria, Enterococcus faecium SF68, Saccharomyces boulardii)
Number of subjects: 0
Study 17311979 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 0
Study 15081569 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran 30 mg
Number of subjects: 120
Study 15081569 — intervention group
Group type: EXPERIMENTAL
Intervention: ximelagatran 60 mg
Number of subjects: 120
Study 15081569 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hirudin
Number of subjects: 120
Study 15081569 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 120
Study 15081569 — intervention group
Group type: COMPARATOR
Intervention: control (tap water)
Number of subjects: 120
Study 12674781 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustical technique measuring transmission properties of acoustic waves in the hip joints
Number of subjects: 87
Study 9825816 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza)
Number of subjects: 216
Study 9825816 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 216
Study 7695954 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg/day
Number of subjects: 50
Study 7695954 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 50
Study 2577382 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 36
Study 2577382 — intervention group
Group type: COMPARATOR
Intervention: Control (no OK-432)
Number of subjects: 36
Study 4364175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (6 g daily for 7 days)
Number of subjects: 45
Study 4364175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31782535 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 88
Study 31288902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist counseling
Number of subjects: 19
Study 31288902 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 19
Study 28161530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (60,000 IU/month or 120,000 IU/month)
Number of subjects: 0
Study 28161530 — intervention group
Group type: COMPARATOR
Intervention: Control arm (18,000 IU/month)
Number of subjects: 0
Study 25023847 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate formulation A (2g)
Number of subjects: 50
Study 25023847 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate formulation B (2g)
Number of subjects: 50
Study 22836732 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 208
Study 22836732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 208
Study 22836732 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 208
Study 21924709 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased elaboration of components in explanations
Number of subjects: 0
Study 21924709 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental manipulation of elaboration
Number of subjects: 0
Study 21924709 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical elaboration
Number of subjects: 0
Study 19750190 — intervention group
Group type: EXPERIMENTAL
Intervention: MOBILE-Self-Monitored
Number of subjects: 17
Study 19750190 — intervention group
Group type: COMPARATOR
Intervention: MOBILE-Coached
Number of subjects: 17
Study 19750190 — intervention group
Group type: COMPARATOR
Intervention: MOBILE-Coached and MOBILE-Self-Monitored
Number of subjects: 17
Study 16508278 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mmol/l calcium lactate prerinse
Number of subjects: 5
Study 16508278 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mmol/l calcium lactate prerinse
Number of subjects: 5
Study 16508278 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mmol/l calcium lactate prerinse
Number of subjects: 5
Study 16508278 — intervention group
Group type: COMPARATOR
Intervention: NaF control without a prerinse
Number of subjects: 5
Study 12861344 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Pentastarch infusion (500 ml)
Number of subjects: 12